FindTrial
Sign In

RotaTeq

BIOLOGICAL7 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), MCM Vaccines B.V., Sanofi Pasteur, a Sanofi Company, National Institute of Pediatrics, Mexico, Sanofi

Conditions

Bacterial InfectionsHIV InfectionNeisseria MeningitidisPneumococcal ImmunizationRotavirus InfectionRotavirus VaccineVirus Diseases

Phase 2

Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers
CompletedNCT00880698
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection, Rotavirus Infection
Start: 2009-12-31End: 2014-01-31Updated: 2021-11-05

Phase 3

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
CompletedNCT01341639
MCM Vaccines B.V.Bacterial Infections, Virus Diseases
Start: 2011-05-26End: 2013-03-13Updated: 2019-04-30
Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
CompletedNCT01839175
Sanofi Pasteur, a Sanofi CompanyBacterial Infections, Neisseria Meningitidis, Virus Diseases
Start: 2013-04-30End: 2015-02-28Updated: 2017-09-11
Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs
CompletedNCT02193061
National Institute of Pediatrics, MexicoRotavirus Vaccine
Start: 2013-11-30End: 2017-11-30Updated: 2018-08-08
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Active, not recruitingNCT06736041
Sanofi Pasteur, a Sanofi CompanyPneumococcal Immunization
Start: 2024-12-18End: 2027-05-17Updated: 2026-02-18
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Active, not recruitingNCT06824181
SanofiPneumococcal Immunization
Start: 2025-02-27End: 2027-09-10Updated: 2026-02-13
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
RecruitingNCT06824194
SanofiPneumococcal Immunization
Start: 2025-02-18End: 2027-05-12Target: 2320Updated: 2026-03-03

Related Papers

Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants
Frontiers in Public Health2024-02-23
B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine
UNC Libraries2020-04-16
Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers
Vaccine2018-11-2212 citations
B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine
Frontiers in Immunology2018-01-1914 citations
A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
2017-02-0122 citations
Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
2016-12-099 citations